title: Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus.
abstract: The role of cardiovascular risk reduction in patients with diabetes mellitus is significant as several factors have been found to promote accelerated atherosclerosis in persons with diabetes including hyperglycemia-induced endothelial dysfunction, impaired fibrinolysis, increased platelet aggregation, plaque instability, dysfunctional arterial remodeling, and fibrotic and calcified coronary arteries. Recent attention has focused on identifying a cardiovascular biomarker that would propose a better noninvasive way to detect or visualize subclinical cardiovascular disease and prevent cardiovascular events. This article reviews the use of commonly used cardiovascular risk assessment tools and emerging biomarkers including coronary artery calcium scanning, metabolomics, genomics, and the role of optimal revascularization and risk reduction strategies and their impact on reducing risk in patients with cardiovascular disease and diabetes.
authors.affiliation: Division of Cardiology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.
authors.forename: Shailesh
authors.initials: S
authors.lastname: Nandish
authors.forename: Jamison
authors.initials: J
authors.lastname: Wyatt
authors.forename: Oscar
authors.initials: O
authors.lastname: Bailon
authors.forename: Mike
authors.initials: M
authors.lastname: Smith
authors.forename: Rene
authors.initials: R
authors.lastname: Oliveros
authors.forename: Robert
authors.initials: R
authors.lastname: Chilton
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D050197:Atherosclerosis / Q000453:epidemiology / Q000378:metabolism; D015415:Biomarkers / Q000032:analysis; D002118:Calcium / Q000032:analysis; D003331:Coronary Vessels / Q000737:chemistry; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000453:epidemiology* / Q000378:metabolism / Q000517:prevention & control; D018450:Disease Progression; D023281:Genomics; D006801:Humans; D008019:Life Style; D055432:Metabolomics; D009203:Myocardial Infarction / Q000453:epidemiology / Q000378:metabolism; D017202:Myocardial Ischemia / Q000628:therapy; D009204:Myocardial Revascularization; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D040242:Risk Reduction Behavior
chemical_list: D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D002118:Calcium